BioLynx
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BioLynx - overview
Established
2015
Location
Hangzhou, Zhejiang, China
Primary Industry
Biotechnology
About
Established in 2015 and based in Hangzhou, China, BioLynx operates as a biotechnology company that focuses on developing in vitro diagnostic reagents and antibody. In 2016, the company established a scientific antibody research and development and production base. In 2020, it acquired EU CE certification. In July 2024, the firm closed a strategic investment.
The company's main products include LYNX310 equipment, immunochromogenic systems and auxiliary reagents, and RUO reagents. The LYNX310 device provides full-process services from baking to counterstaining in immunohistochemistry experiments. The company’s revenue is generated by providing antibody screening solutions.
Current Investors
Puhua Capital, Share Capital, Bio4p
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.biolynx.cn
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.